Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional botulinum toxin A vs triamcinolone injection for hypertrophic scars and keloids
IRCT20120215009014N554Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A and triamcinolone in Hypertrophic Scar (HS) and keloid (2 arms), sponsored by Hamadan University of Medical Sciences. Started Apr 2025; status: completed.
02
Drugs
botulinum toxin type Atriamcinolone
03
Conditions
Hypertrophic Scar (HS)keloid
Beyond the preview
Go deeper on IRCT20120215009014N554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N554.